Summary

This BMJ investigation asks whether the US claim of medical agreement on treating gender distress in young people is backed by evidence. Block looks at the three most-quoted US guidance documents (from WPATH, the American Academy of Pediatrics and the Endocrine Society) and interviews experts on how they were made. Research reviews behind these guidelines rated the evidence for teenagers as low or very low quality, yet strong recommendations were made, and the pediatrics statement was not based on a formal review of the research. Meanwhile Sweden, Finland and NHS England were restricting medical treatment. It documents real weaknesses in the US guidelines and showed a major journal took the debate seriously. But it is journalism: the reporter chose the sources and examples, some figures (such as 20–30% stopping hormones) come from limited studies, and some readers called it biased.

Key findings

• 美國的醫學團體（WPATH、美國小兒科學會和內分泌學會）支持對未成年人使用青春期阻斷劑、跨性別荷爾蒙，以及在某些情況下進行手術，而瑞典和芬蘭則轉向以心理照護優先，並將手術限於成人。
• 內分泌學會使用正式的證據評等系統，將其所有針對青少年的建議所依據的證據評為「低」或「極低」，卻有時提出強力建議。該評等系統的共同創立者 Gordon Guyatt 表示，這種情況應該很少見，且要清楚說明。
• WPATH 2022 年的指引沒有證據評等系統。指引專家 Mark Helfand 發現有些陳述與指引自己的研究審查者「相互矛盾」，審查者把荷爾蒙對生活品質、憂鬱和焦慮影響的證據評為低品質。
• 美國小兒科學會 2018 年政策聲明的主要作者表示，其過程並不完全算是對研究的正式審查。領先的證據審查組織 Cochrane 在專家審核後，拒絕發表一項擬議的青春期阻斷劑審查。
• 麥克馬斯特大學對 61 項研究審查所做的摘要，由佛羅里達州的醫療補助（公共健康保險）機構出資，發現關於年輕人的阻斷劑、荷爾蒙和手術存在「極大的不確定性」。
• 兩項近期研究（英國一家家庭醫師診所的稽核，以及美國軍方藥局紀錄）顯示，20–30% 的患者可能在幾年內停用荷爾蒙，但這衡量的是停藥，而不是後悔或去過渡。
• 臨床人員描述了更快的醫療處置和更少的心理健康評估。在西雅圖兒童醫院診所的一項研究中，三分之二的青少年在首次就診後 12 個月內開始使用荷爾蒙。

Conclusion

This investigative report from The BMJ concludes that despite claims of consensus, gender-affirming medical treatments for minors with gender dysphoria lack strong evidence-based support. Key findings include: (1) US medical organizations (WPATH, AAP, Endocrine Society) endorse gender-affirming care including puberty blockers, hormones, and surgeries, while several European countries (Sweden, Finland, France, UK) have moved to restrict medical interventions for minors, prioritizing psychological care; (2) systematic reviews commissioned by guideline bodies found evidence quality to be "low" or "very low," with experts criticizing the misapplication of "evidence-based" labeling to recommendations not meeting rigorous standards; (3) the surge in treatment of minors—particularly birth-registered females with no prior history of gender dysphoria—has outpaced research, with long-term outcomes unknown and detransition rates potentially as high as 20-30%; (4) clinical practice has shifted toward rapid medicalization, with concerns about inadequate assessment and perfunctory informed consent processes; and (5) prominent evidence-based medicine experts conclude that when rigorous systematic reviews find "we don't know," claims of certainty are not evidence-based, and consensus-based guidelines should not be called evidence-based.